EA201991175A1 - Применение в медицине интерферона-лямбда для лечения фиброза - Google Patents
Применение в медицине интерферона-лямбда для лечения фиброзаInfo
- Publication number
- EA201991175A1 EA201991175A1 EA201991175A EA201991175A EA201991175A1 EA 201991175 A1 EA201991175 A1 EA 201991175A1 EA 201991175 A EA201991175 A EA 201991175A EA 201991175 A EA201991175 A EA 201991175A EA 201991175 A1 EA201991175 A1 EA 201991175A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fibrosis
- interferon
- lambda
- treatment
- medicine
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 3
- 230000004761 fibrosis Effects 0.000 title abstract 3
- 230000003510 anti-fibrotic effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1621728.3A GB201621728D0 (en) | 2016-12-20 | 2016-12-20 | Methods |
| PCT/EP2017/083949 WO2018115199A1 (en) | 2016-12-20 | 2017-12-20 | Medical use of interferon-lambda for the treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991175A1 true EA201991175A1 (ru) | 2019-11-29 |
Family
ID=58284677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991175A EA201991175A1 (ru) | 2016-12-20 | 2017-12-20 | Применение в медицине интерферона-лямбда для лечения фиброза |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190374610A1 (https=) |
| EP (1) | EP3558342B1 (https=) |
| JP (3) | JP7609556B2 (https=) |
| CN (1) | CN110381985A (https=) |
| AR (1) | AR110404A1 (https=) |
| BR (1) | BR112019012084A2 (https=) |
| CA (1) | CA3044949A1 (https=) |
| EA (1) | EA201991175A1 (https=) |
| ES (1) | ES3019566T3 (https=) |
| GB (1) | GB201621728D0 (https=) |
| TW (1) | TW201828973A (https=) |
| UY (1) | UY37534A (https=) |
| WO (1) | WO2018115199A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7674628B2 (ja) | 2016-02-19 | 2025-05-12 | イーアイティー・ファーマ・インコーポレイテッド | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3375452B1 (en) * | 2017-03-16 | 2025-01-08 | Evangelos Andreakos | Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder |
| EP3849592A4 (en) * | 2018-08-23 | 2022-08-24 | Exalt Therapeutics, LLC | MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING FRAGMENT AND THEIR USES |
| EP3999101A1 (en) * | 2019-07-18 | 2022-05-25 | ENYO Pharma | Method for decreasing adverse-effects of interferon |
| CN110882381B (zh) * | 2019-12-18 | 2020-11-17 | 中国人民解放军陆军军医大学第一附属医院 | 重组IFN-λ1蛋白在制备防治炎症性骨丢失药物中的应用 |
| WO2021119749A1 (en) * | 2019-12-20 | 2021-06-24 | The Council Of The Queensland Institute Of Medical Research | Treatment of gastrointestinal disease |
| CN114736878B (zh) * | 2021-01-07 | 2024-04-19 | 秦皇岛摩登狗生物科技有限公司 | 共表达猪干扰素l3和猪白介素22重组杆状病毒及应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| MXPA03009082A (es) | 2001-04-06 | 2004-11-22 | Maxygen Holdings Ltd | Variantes polipeptidicas de interferon gamma. |
| EP1551369A4 (en) | 2002-08-28 | 2007-05-09 | Intermune Inc | COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES |
| AU2003225670A1 (en) | 2003-02-28 | 2004-09-28 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
| AU2003299962A1 (en) | 2003-02-28 | 2004-09-28 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
| WO2004105684A2 (en) | 2003-05-16 | 2004-12-09 | Intermune, Inc. | Combination therapy for proliferative disorders |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US20070258946A1 (en) * | 2003-12-23 | 2007-11-08 | Blatt Lawrence M | Combination Therapy for Treating Hepatitis C Virus Infection |
| WO2005110478A2 (en) | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| EP1991679A2 (fr) | 2006-03-08 | 2008-11-19 | Biomethodes | Variants de l'interferon- gamma humain (ifngamma) |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| AU2009255994B2 (en) * | 2008-06-05 | 2014-07-17 | Bristol-Myers Squibb Company | Use of pegylated Type III Interferons for the treatment of hepatitis C |
| US20110263484A1 (en) | 2008-10-13 | 2011-10-27 | Zymogenetics, Inc. | Single chain fc type iii interferons and methods of using same |
| WO2010048468A1 (en) | 2008-10-23 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Deuterated macrocyclic inhibitors of viral ns3 protease |
| EP2350124A1 (en) * | 2008-11-20 | 2011-08-03 | Zymogenetics, Inc. | Il-29 mutants and uses thereof |
| WO2011075605A2 (en) * | 2009-12-18 | 2011-06-23 | Alios Biopharma, Inc. | Hyperglycosylated interferon variants and methods of use |
| IT1400236B1 (it) | 2010-05-10 | 2013-05-24 | Univ Bari | Impiego di composti noti per il trattamento dell'insufficienza renale cronica(irc) |
| CN102584979B (zh) * | 2011-01-18 | 2015-10-14 | 北京凯因科技股份有限公司 | PEG化干扰素λ |
| US9678074B2 (en) | 2012-03-28 | 2017-06-13 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Interferon-λ4 (IFNL4) protein, related nucleic acid molecules, and uses thereof |
| JP7674628B2 (ja) | 2016-02-19 | 2025-05-12 | イーアイティー・ファーマ・インコーポレイテッド | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
-
2016
- 2016-12-20 GB GBGB1621728.3A patent/GB201621728D0/en not_active Ceased
-
2017
- 2017-12-20 BR BR112019012084-0A patent/BR112019012084A2/pt not_active IP Right Cessation
- 2017-12-20 WO PCT/EP2017/083949 patent/WO2018115199A1/en not_active Ceased
- 2017-12-20 AR ARP170103597A patent/AR110404A1/es unknown
- 2017-12-20 UY UY0001037534A patent/UY37534A/es not_active Application Discontinuation
- 2017-12-20 US US16/469,236 patent/US20190374610A1/en not_active Abandoned
- 2017-12-20 EP EP17829194.4A patent/EP3558342B1/en active Active
- 2017-12-20 EA EA201991175A patent/EA201991175A1/ru unknown
- 2017-12-20 ES ES17829194T patent/ES3019566T3/es active Active
- 2017-12-20 CN CN201780077416.5A patent/CN110381985A/zh active Pending
- 2017-12-20 CA CA3044949A patent/CA3044949A1/en not_active Abandoned
- 2017-12-20 JP JP2019532000A patent/JP7609556B2/ja active Active
- 2017-12-20 TW TW106144926A patent/TW201828973A/zh unknown
-
2022
- 2022-03-23 JP JP2022046767A patent/JP2022081677A/ja active Pending
-
2023
- 2023-06-29 US US18/343,944 patent/US11975046B2/en active Active
-
2024
- 2024-08-01 JP JP2024125837A patent/JP2024156844A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7609556B2 (ja) | 2025-01-07 |
| GB201621728D0 (en) | 2017-02-01 |
| JP2024156844A (ja) | 2024-11-06 |
| WO2018115199A1 (en) | 2018-06-28 |
| EP3558342B1 (en) | 2025-01-29 |
| US20190374610A1 (en) | 2019-12-12 |
| BR112019012084A2 (pt) | 2019-11-12 |
| US11975046B2 (en) | 2024-05-07 |
| UY37534A (es) | 2018-09-28 |
| TW201828973A (zh) | 2018-08-16 |
| EP3558342A1 (en) | 2019-10-30 |
| JP2022081677A (ja) | 2022-05-31 |
| CA3044949A1 (en) | 2018-06-28 |
| US20240000893A1 (en) | 2024-01-04 |
| AR110404A1 (es) | 2019-03-27 |
| CN110381985A (zh) | 2019-10-25 |
| JP2020511415A (ja) | 2020-04-16 |
| ES3019566T3 (en) | 2025-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
| MX2024010140A (es) | Nuevos metodos. | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| ZA201700196B (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| MX2022007989A (es) | Composiciones y metodos para tratar pterigion. | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| EA201790737A1 (ru) | Комбинированная терапия | |
| EA201790575A1 (ru) | Триазолопиразиноны в качестве ингибиторов pde1 | |
| EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| EA201792157A1 (ru) | Имидазопиразиноны в качестве ингибиторов pde1 | |
| EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
| MX2017004558A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| MX2019005779A (es) | Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina. | |
| PH12018501443A1 (en) | Methods of administering hepcidin | |
| EA201892297A1 (ru) | Способы лечения холестатических и фибротических заболеваний | |
| JOP20190056B1 (ar) | مركبات للاستخدام في علاج القصور الكلوي الحاد | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний |